Literature DB >> 2713213

Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.

P A Soons1, A G de Boer, P van Brummelen, D D Breimer.   

Abstract

1. In nine healthy male subjects the kinetics of nitrendipine were assessed after i.v. administration and its absorption profile was studied when given by a tablet formulation and by an osmotic pumping device (Osmet) with a zero-order in vitro release of 2.62 +/- 0.19 mg h-1 for 13 h. 2. Plasma concentrations of nitrendipine and its pyridine metabolite, heart rate and blood pressure were determined at regular intervals after drug administration. 3. After i.v. nitrendipine, the plasma concentration declined triexponentially with a mean terminal elimination half-life of 11.7 +/- 5.4 h. The mean systemic plasma clearance was 1.47 +/- 0.22 l min-1. 4. Administration of the Osmet resulted in a relatively smooth plasma concentration-time profile in comparison with the tablet. The mean plateau concentration was 2.63 +/- 1.31 ng ml-1 and the duration of this plateau was 10.7 +/- 3.2 h. The intake of food gave rise to a transient increase of the plasma concentration of both nitrendipine and its pyridine metabolite. 5. The mean bioavailability of nitrendipine from the Osmet (8.2 +/- 1.6%) was lower than from the tablet (11.1 +/- 4.5%), which is probably due to release of nitrendipine in lower parts of the G.I. tract where absorption is not or less possible. 6. Intravenous administration caused a transient decrease in DBP of 26 +/- 4%, accompanied by a maximal reflex tachycardia of 46 +/- 17%. No clear haemodynamic effects were observed after oral administration. The Osmet produced less side-effects (headache) than the tablet.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713213      PMCID: PMC1379778          DOI: 10.1111/j.1365-2125.1989.tb05349.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

2.  Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration.

Authors:  G Mikus; C Fischer; B Heuer; C Langen; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

3.  Gas chromatographic analysis of nitrendipine and its pyridine metabolite in human plasma.

Authors:  P A Soons; D D Breimer
Journal:  J Chromatogr       Date:  1988-07-15

4.  ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.

Authors:  R J Francis
Journal:  Comput Programs Biomed       Date:  1984 Feb-Apr

5.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; M Danhof; N P Vermeulen; D D Breimer
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

6.  Mathematical basis of point-area deconvolution method for determining in vivo input functions.

Authors:  D P Vaughan; M Dennis
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

7.  Zero-order rectal delivery of theophylline in man with an osmotic system.

Authors:  L G de Leede; A G de Boer; S L van Velzen; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

8.  Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system.

Authors:  C H Kleinbloesem; J van Harten; L G de Leede; P van Brummelen; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

9.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

10.  Rectal and intravenous propranolol infusion to steady state: kinetics and beta-receptor blockade.

Authors:  L G de Leede; C C Hug; S de Lange; A G de Boer; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

View more
  8 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Racemic therapeutics--ethical and regulatory aspects.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

4.  Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.

Authors:  V Mast; C Fischer; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

5.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

6.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.

Authors:  P A Soons; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Influence of input rates on (+/-)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers.

Authors:  V Carrara; H Porchet; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.